A nonrandomized, unblinded, interventional pilot study evaluated IFN-α2b therapy for meningoencephalitis produced by SLEV and suggested a beneficial effect on the early neurologic course of the disease, indicating that two weeks of treatment were well tolerated [299]. This evidence concerns the gene IFNA2 and meningoencephalitis.